genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2024
Alexion Pharmaceuticals
GEN Edge
StockWatch: Wall Street’s Leaders and Laggards of 2024
Drug Discovery
Novartis, Voyager Ink Up-to-$1.3B Expansion of Neuro Gene Therapy Collaboration
Genome Editing
LogicBio Acquired by Alexion, AstraZeneca Rare Disease
Drug Discovery
Alexion Inks Collaborations Totaling $1.3B+ with Affibody, Zealand
Drug Discovery
Alexion to Eliminate 7% of Workforce
A-Lists
Top 25 Biotech Companies of 2015
Insights
The High Cost of Rare Disease Drugs
A-Lists
What the Top 15 Biopharma CEOs Are Making
Drug Discovery
FDA Clears Alexion’s Soliris for All Patients with Atypical Hemolytic Uremic Syndrome
Drug Discovery
Alexion Pads Biologic R&D with $111M Acquisition of Taligen
1
2
Page 1 of 2
Scroll Up